SEC Form 4 · accession 0000897069-26-001554
Processa Pharmaceuticals, Inc. · PCSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George K Ng
Officer — Chief Executive Officer · Director
Period of report
Jul 26, 2026
Accepted (ET)
Jul 28, 2026 · 8:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001533743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 15,492 | D | ||
| Common Stock | holding | — | — | — | 3,488 | I | George Ng IRRA FOB George Ng | |
| Common Stock | holding | — | — | — | 800 | I | Ng Cha Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | $0.00 | Jul 26, 2026 | A | 9,384 | A | — | — | Common Stock | 9,384 | 21,224 | D |
| Stock Options (Right to Buy)F3,F2 | $4.96 | holding | — | — | — | — | — | Common Stock | 30,720 | 30,720 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
- F2Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
- F3Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.